Symbols

CMND

Clearmind Medicine·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CMND

Clearmind Medicine Inc.

A pharmaceutical company developing a new psychedelic drug

Industry

Life Science Tools and Services

Established Date

07/18/2017

Listing Date

11/15/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

10-31

Website

www.clearmindmedicine.com

Security Type

Common stock

Office address

101–1220 West 6th Avenue, Vancouver, British Columbia V6H1A5

Business

Introduction

Clearmind Medicine Inc., incorporated in British Columbia on July 18, 2017, is a clinical-stage pharmaceutical company dedicated to advancing the development of novel psychedelic drugs to address prevalent but under-treated health conditions, focusing on alcohol use disorder (AUD). The company's proprietary compound, MEAI, is a non-hallucinogenic neuroplastin that is being investigated for its potential to treat AUD, binge drinking, eating disorders and metabolic conditions, as well as as as an alcohol substitute for consumers. Clearmind aims to provide innovative, safe, and effective treatments that can reduce the global economic and health burden associated with drinking, which kills millions of people every year and incurs significant health care costs. The company completed a series of IND-enabling preclinical studies in the United States and China, including pharmacokinetic, toxicological and metabolic studies in animal models to evaluate the safety and efficacy of MEAI. Clinical progress includes obtaining approval from the Israeli Ministry of Health and the U.S. FDA to start the first human phase I/II trial of AUD using CMND-100, which was conducted at leading research centers such as Yale University, Johns Hopkins University, and multiple sites in Israel such as Sourasky and Hadassah Medical Center in Tel Aviv, Israel. The company's ongoing research supports its mission to develop translational therapies for mental health and substance-related diseases.

Company Financials

EPS

CMND has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected 0, missing expectations. The chart below visualizes how CMND has performed over recent quarters, highlighting trends in earnings surprises.